INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. and its officers or directors, following a significant stock price drop after negative FDA news [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Savara Inc. and is looking into claims of securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance - On May 27, 2025, Savara announced it received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, leading to a stock price decline of $0.90 per share, or 31.69%, closing at $1.94 per share [3].